中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2013, Vol. 48 Issue (2) :96-100    DOI:
���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
�յ��Ӷ԰������д�����л�����Ӱ�����
���ϼ�����׷ᣬ�ẓ̇���־��
1.������ɫֲ����Ч�ɷ�����Ʒ���̼����о����ģ����� 730030�� 2.��������ѧ������ѧ�빤��ѧԺ������ 730050
LI Cui-xia��WANG Zhao-feng�� ZHANG Ji��Li Zhi-zhong

Download: PDF (0KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �о���ͬŨ���յ��ӶԲ�ͬ��ֳ�׶ΰ������д�����л������۵�Ӱ�졣���� ��1/2 MSΪ������������������������20��30��40 d�󣬷ֱ�����Դ�յ��������������MeJA����ˮ����(SA)�ͿǾ���(Chs)�԰���������յ���������ȡ������Ч�ɷֽ�����ȡ��������ɫ��-���������Ǽ�ⲻͬ��ֳ�׶��յ��ӶԴ�����л������۵�Ӱ�졣��� ����ȡҺ�м�⵽46�ֻ�������жԱȷ����˺�������1%��12�ֻ��������3���յ��Ӷ��԰������Ϊ����ķ����廯��������Ч����Ϊ���ԣ���1-�׻�-3-��1-�׻��һ�������1-�׻�-4-4��1-�׻��һ���-1��4-����ϩΪ������������໯�������ϩ�໯����Ч��ʮ�����ԡ����� ��ͬ���յ��Ӷ԰������д�����л���ﺬ�����������졣
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
���ϼ
���׷�
�ż�
��־��
�ؼ����� �յ���   ������   ���������   ˮ����   �Ǿ���   ������л����   ����ɫ��-��������     
Abstract�� OBJECTIVE To investigate the effect of elicitors on secondary metabolites accumulation at different proliferation stages of thyme. METHODS The thyme was induced by jasmonic acid methyl ester��salicylic acid and chitosan respectively after being culture on 1/2 MS basal medium for 20�� 30 and 40 d�� and secondary metabolites were extracted and examined by GC-MS. RESULTS Forty-six compounds were identified in the solution. It was found through comparison of 12 compounds with contents more than 1% that three inducers significantly increased the contents of aromatic compounds represented by thymol�� oxidation terpenoids and terpenes compounds represented by benzene�� 1-methyl-3-(1-methylethyl) and 1�� 4-cyclohexadiene 1-methyl-4-(1-methylethyl). CONCLUSION The secondary metabolites of thyme are affected significantly by elicitors.
Keywords�� elicitor,   Thymus serpyllum L.,   jasmonic acid methyl ester,   salicylic acid,   chitosan,   secondary metabolites,   GC-MS     
�ո�����: 2012-01-14;
��������:������Ȼ��ѧ����������Ŀ��31160087��������ʡ�Ƽ�����Ȼ��ѧ����������Ŀ(0803RJZA038)������ʡ����������1101-06��������ʦ����ѧ�Ƽ����¹Ǹ���Ŀ (NWNU-KJCXGC-03-58)����
���߼��: ���ϼ��Ů��˶ʿ �о��������ﻯѧ��øѧ��ֲ���о� ��ͨѶ���ߣ��ẓ̇�Ů���о�Ա �о�������Ȼ���ﻯѧ�͸߷��ӻ�ѧ Tel/Fax����0931- 7971414�� E-mail��zhangj@nunu.edu.cn
���ñ���:   
���ϼ, ���׷�, �ż̵� .�յ��Ӷ԰������д�����л�����Ӱ�����[J]  �й�ҩѧ��־, 2013,V48(2): 96-100
LI Cui-Xia, WANG Zhao-Feng, ZHANG Ji etc .Effect of Elicitors on the Contents of Secondary Metabolites in Thymus[J]  Chinese Pharmaceutical Journal, 2013,V48(2): 96-100
��
[1] NBS. 2010 communique of the sixth national census data(No.1). 2011-04-28. http��//www.stats.gov.cn/tjfx/jdfx/t20110428_402722253.htm.[2] ICH. Clinical Investigation of Medicinal Products in the Pediatric Population.2000-07-20. http��//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Effic-acy/E11/Step4/E11_Guideline.pdf.[3] DONG Y. Discussion on the safety of pediatric drugs. Chin J Pharmaovigilance(�й�ҩ�ᆵ��)�� 2009��6(7)��401-403.[4] ICH. Dose-Response Information to Support Drug Registration. 1994-03-10. ht-tp��//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E4/Step4/E4_Guideline.pdf.[5] ICH. Ethnic Factors in the Acceptability of Foreign Clinical Data. 1998-02-05.http��//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/St-ep4/E5_R1__Guideline.pdf.[6] ICH. Good Clinical Practice. 1996-06-10. http��//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.[7] ICH. Choice of Control Group and Related Issues in Clinical Trials. 2000-07-20. http��//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.[8] ICH. Statistical Principles for Clinical Trials. 1998-02-05. http��//www.ich.org/fi-leadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.[9] SFDA. Good clinical practice. 2003-08-06. http��//www.sfda.gov.cn/WS01/CL/0053/24473.html. SFDA. The issuance of the notice of the guiding principles of vaccine clinical trials . 2004-12-03. http��//www.sfda.gov.cn/WS01/CL/0844/10307.html. SFDA. The issuance of the Guideline on Management of Phase I Clinical Trial of D-rugs (interim) . 2011-12-02. http��//www.sda.gov.cn/WS01/CL/0055/10307.html. CHEN Q�� DU G�� ZHANG D R. The status and progress of the children's drug use a-nd its clinical research. Her Med (ҽҩ����)�� 2011��30(5)��593-597. TIAN C H�� SHEN L. The pediatric drug research and drug safety. Chin J Pharmacovigilance(�й�ҩ�ᆵ��)�� 2009��6(9)��518-521. SFDA. The accreditation review of clinical of drug clinical trial institution qualificatio-n(No.1).2012-02-29. http��//www.sda.gov.cn/WS01/CL/0069/69642.html. YANG L�� LUO C�� CHEN J. Pediatric exclusivity system(��). Chin New Drug J(�й���ҩ��־)�� 2009��18(8)��677-680. YANG Z M�� ZHANG P P. The current approval status and characteristic analysis of pediatric drugs overseas. Chin Pharm J(�й�ҩѧ��־)�� 2012��47(10)��745-748.
[2] KUS J V�� ZATON K�� SARKAR R�� et al. Age-related resistance in Arabidopsis is a developmentally regulated defense response to pseudomonas syringae. Plant Cell�� 2002�� 14��2���� 479-490��
[3] ZHANG J�� LIU A P�� YANG Y L�� et al. Studies on the essential chemical constituents Thymus serpyllum L. . J Sichuan Univ(�Ĵ���ѧѧ��)�� 2004�� 41(4)�� 890-892.
[4] WANG H�� YE H C�� LI G F. Elicitors��action modes and their applliction in plant tissue culture . Chin Bull Bot(ֲ��ѧͨ��)�� 1999�� 16 (1)�� 11-18.
[1] �����;��Ө;����;��˫��.����ɫ��-�������÷��ⶨ��������192��ũҩ�����[J]. �й�ҩѧ��־, 2012,47(8): 613-619
[2] �޽��� Ф��� ��˳�� ������ .ɸѡ�յ���ľ����������������о�[J]. �й�ҩѧ��־, 2012,47(5): 335-337
[3] ���壬ʩТ����蹳������ٷɣ����Ӿ�.�Ծ��Ҷ���Ϊ���ʵ�Ũ������ˮ�������Ĵ���ɸѡ���ȶ��������о�[J]. �й�ҩѧ��־, 2012,47(22): 1829-1833
[4] �޽�������Ф�������˳��*.����յ���ľ����������Ұ��ʵ�������[J]. �й�ҩѧ��־, 2012,47(20): 1614-1616
[5] ����ϼ����־ϲ�����Ļۣ���ˮ�У�֣����.������������˳�����������������Ʊ����������������������[J]. �й�ҩѧ��־, 2012,47(18): 1483-1488
[6] ����ϲ;����.�ȼ׻��Ǿ�����Ϊҩ��������о���չ[J]. �й�ҩѧ��־, 2012,47(10): 804-808
[7] ��ΰ ������ ¬��Ƽ ��ΰ ����Ӣ ���� �ᄚ�� ���� ����.UV-B�յ���������Ҷʮ����Ҷ������л�����ۻ�Ӱ����о�[J]. �й�ҩѧ��־, 2012,47(1): 19-22
[8] ������ ���� ����Ԫ �����٩~.�����ǻ��Ǿ���-�������ż����ĺϳ������[J]. �й�ҩѧ��־, 2011,46(21): 1677-1680
[9] ֣��Ƽ ������ ��ܿ�� �ィ��.���ȵ��ص�����𤸽�Ծ�����-�ǻ��������������Ʊ�����������������[J]. �й�ҩѧ��־, 2011,46(18): 1421-1426
[10] ����� ̷���� ���� ��ƽ�� ����ɽ .��炙��Ǿ��ǶԳ��������绯ø�Ļ�ѧ�����о�[J]. �й�ҩѧ��־, 2011,46(14): 1117-1121
[11] ��Ӣ�� �־���.һ�������������������ˮ���������������ϸ�����������Ҵ�������ϳɵ�Ӱ��[J]. �й�ҩѧ��־, 2011,46(14): 1069-1073
[12] ������ ���� ������ ��ѩ�� ��ٻ.����ݼ���/���̴�����-�Ǿ��ǹ��������׽������Ʊ��������⿹��������[J]. �й�ҩѧ��־, 2011,46(13): 1015-1019
[13] ������ ����.�����Ǿ��������涡����΢�ҵ��Ʊ��������ͷŶ��о�[J]. �й�ҩѧ��־, 2010,45(7): 531-533
[14] �ྴı ������ ������ ������ ������ ��һ.�Ҷ����Ǿ���-���̴���֦���ض�������Ծۼ����������Ʊ������������ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2010,45(4): 277-282
[15] ������ ������ ��ռ�� ף����.�������ᆱ��������׼�����о�[J]. �й�ҩѧ��־, 2010,45(2): 98-100
Copyright 2010 by �й�ҩѧ��־